Cancer Research Annual Meeting 2010  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 69, 2000, March 1, 2009. Published Online First February 24, 2009;
doi: 10.1158/0008-5472.CAN-08-2360
© 2009 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow All Versions of this Article:
0008-5472.CAN-08-2360v1
69/5/2000    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gobert, M.
Right arrow Articles by Ménétrier-Caux, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gobert, M.
Right arrow Articles by Ménétrier-Caux, C.

Immunology

Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome

Michael Gobert1,2,3,4, Isabelle Treilleux5, Nathalie Bendriss-Vermare1,2,3,4, Thomas Bachelot1,8, Sophie Goddard-Leon5, Vanessa Arfi1,2,3,4, Cathy Biota1,2,3,4, Anne Claire Doffin1,2,3,4, Isabelle Durand1,2,3,4, Daniel Olive7, Solène Perez8, Nicolas Pasqual8, Christelle Faure6, Isabelle Ray-Coquard6, Alain Puisieux1,2,3,4, Christophe Caux1,2,3,4, Jean-Yves Blay1,2,3,4 and Christine Ménétrier-Caux1,2,3,4

1 INSERM, U590; 2 Centre Léon Bérard, Equipe Cytokines et Cancers; 3 Université Lyon 1, ISPB; 4 IFR62; 5 Centre Léon Bérard, Département D'anatomie et Cytologie Pathologiques; 6 Centre Léon Bérard, Département d'Oncologie Médicale, Lyon, France; 7 Laboratoire d'Immunologie des Tumeurs et Centre INSERM de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France; and 8 ImmunID Technologies, Grenoble, France

Requests for reprints: Christine Ménétrier-Caux, Centre Léon Bérard, Equipe Cytokines et Cancers, INSERM, U590, Lyon F-69008, France. Phone: 33-4-78-78-27-20; Fax: 33-4-78-78-27-50; E-mail: caux{at}lyon.fnclcc.fr.

Key Words: activated Treg • ICOS • CCL22 recruitment • local immunosuppression • breast carcinoma

Immunohistochemical analysis of FOXP3 in primary breast tumors showed that a high number of tumor-infiltrating regulatory T cells (Ti-Treg) within lymphoid infiltrates surrounding the tumor was predictive of relapse and death, in contrast to those present within the tumor bed. Ex vivo analysis showed that these tumor-infiltrating FOXP3+ T cells are typical Treg based on their CD4+CD25highCD127lowFOXP3+ phenotype, their anergic state on in vitro stimulation, and their suppressive functions. These Ti-Treg could be selectively recruited through CCR4 as illustrated by (a) selective blood Treg CCR4 expression and migration to CCR4 ligands, (b) CCR4 down-regulation on Ti-Treg, and (c) correlation between Ti-Treg in lymphoid infiltrates and intratumoral CCL22 expression. Importantly, in contrast to other T cells, Ti-Treg are selectively activated locally and proliferate in situ, showing T-cell receptor engagement and suggesting specific recognition of tumor-associated antigens (TAA). Immunohistochemical stainings for ICOS, Ki67, and DC-LAMP show that Ti-Treg were close to mature DC-LAMP+ dendritic cells (DC) in lymphoid infiltrates but not in tumor bed and were activated and proliferating. Furthermore, proximity between Ti-Treg, CD3+, and CD8+ T cells was documented within lymphoid infiltrates. Altogether, these results show that Treg are selectively recruited within lymphoid infiltrates and activated by mature DC likely through TAA presentation, resulting in the prevention of effector T-cell activation, immune escape, and ultimately tumor progression. This study sheds new light on Treg physiology and validates CCR4/CCL22 and ICOS as therapeutic targets in breast tumors, which represent a major health problem. [Cancer Res 2009;69(5):2000–9]




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
J. M. Weiss, T. C. Back, A. J. Scarzello, J. J. Subleski, V. L. Hall, J. K. Stauffer, X. Chen, D. Micic, K. Alderson, W. J. Murphy, et al.
Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment
PNAS, November 17, 2009; 106(46): 19455 - 19460.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. Menetrier-Caux, M. Gobert, and C. Caux
Differences in Tumor Regulatory T-Cell Localization and Activation Status Impact Patient Outcome
Cancer Res., October 15, 2009; 69(20): 7895 - 7898.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2009 by the American Association for Cancer Research.